

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/639,273	08/15/2000	Michael A. Innis	991.001	1822
27476 7.	590 03/27/2002			
Chiron Corporation Intellectual Property - R440 P.O. Box 8097			EXAMINER	
			LAZAR WESLEY, ELIANE M	
Émeryville, CA	A 94662-8097	3097 ART UNIT PAPER NUMBER		
			1646	
			DATE MAILED: 03/27/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No.

09/639,273

Applicant(s)

Innis

Office Action Summary

Examiner
Fliane Lazar-Wesley

Art Unit



		Eliane Lazar-vvesley			
	The MAILING DATE of this communication appears	on the cover sheet with the corr	espondence address		
Period 1	for Reply				
	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	T TO EXPIRE3 MON	TH(S) FROM		
af	nsions of time may be available under the provisions of 37 C ter SIX (6) MONTHS from the mailing date of this communic	cation.			
be	e period for reply specified above is less than thirty (30) days e considered timely. I period for reply is specified above, the maximum statutory				
co	ommunication.		_		
- Any i	re to reply within the set or extended period for reply will, b reply received by the Office later than three months after th Irned patent term adjustment. See 37 CFR 1.704(b).				
Status	anieu patent tenn aujustinent. See 37 Cr n 1.704(b).				
1) 💢	Responsive to communication(s) filed on Jan 7, 20	002	·		
2a) 🗌	This action is FINAL . 2b) 💢 This ac	tion is non-final.			
3) 🗆	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.				
Disposi	tion of Claims				
4) 💢	Claim(s) <u>1-11</u>	is/a	are pending in the application.		
4	4a) Of the above, claim(s) <u>1-6 and 8-11</u>	is/	are withdrawn from consideration.		
5) 🗆	Claim(s)		_ is/are allowed.		
6) 💢	Claim(s) 7		_ is/are rejected.		
7) 🗆	Claim(s)		_ is/are objected to.		
8) 🗆	Claims	are subject to rest	riction and/or election requirement.		
Applica	ition Papers				
9) 🗆	The specification is objected to by the Examiner.				
10)□	The drawing(s) filed on is/ard	e objected to by the Examiner.			
11)	The proposed drawing correction filed on	is: a)□ approve	d b)□ disapproved.		
12)□	The oath or declaration is objected to by the Exam	niner.			
Priority	under 35 U.S.C. § 119				
13)	Acknowledgement is made of a claim for foreign p	priority under 35 U.S.C. § 119(a)-(d).		
a) 🗆	☐ All b)☐ Some* c)☐ None of:				
	1. Certified copies of the priority documents ha	ve been received.			
	2. Certified copies of the priority documents ha	ve been received in Application	No		
	3. ☐ Copies of the certified copies of the priority of application from the International Bure	eau (PCT Rule 17.2(a)).	_		
	ee the attached detailed Office action for a list of the	·			
14)	Acknowledgement is made of a claim for domestic	c priority under 35 U.S.C. § 11	9(e).		
Attachm	ent(s)				
15) 💢 No	otice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Pag	per No(s)		
_	otice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Applicati	on (PTO-152)		
17) 🔲 In	formation Disclosure Statement(s) (PTO-1449) Paper No(s).	20) Other:			

Application/Control Number: 09/639,273 Page 2

Art Unit: 1646

DETAILED ACTION

Applicant's election with traverse of Group VII, claim 7, drawn to TFPI, in Paper No. 6 filed 1.

January 07, 2002 is acknowledged. The traversal is on the ground(s) that the TFPI muteins recited

in claim 11 differ from TFPI by only a small number of amino acids, and share a major portion of

identical amino acids, and that the search is not a burden. This is not found persuasive for the

reasons of record, because the pairwise combination of products are independent and distinct, and

necessitate a different search, and because the searches are not coextensive.

The requirement is still deemed proper and is therefore made FINAL.

Claim 7, as it applies to TFPI, is under consideration.

Priority

2. A statement reading "This is a continuation of Application No. X, filed on" should be

entered following the title of the invention or as the first sentence of the specification. Also, the

current status of all nonprovisional parent applications referenced should be included.

Claim Objections

3. Claim 7 is improperly dependent on non elected claim 1.

Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the

basis for the rejections under this section made in this Office action:

Application/Control Number: 09/639,273

Art Unit: 1646

5.

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Page 3

Claim 7 is rejected under 35 U.S.C. 102(b) as being anticipated by Petersen, Journal of

Biological Chemistry 266(18):13344-13351, 25 June 1995.

Petersen teaches a human tissue factor pathway inhibitor, TFPI, prepared in yeast, which has

the characteristics of the claimed factor VIIa/TF/Xa binding protein. The claim is in product-format,

and as such, it is the novelty and patentability of the instantly claimed product that need to be

established and not that of the recited process steps. <u>In re Brown</u>, 173 USPQ 685 (CCPA 1972); <u>In</u>

re Wertheim, USPQ (CCPA 1976).

6. Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Eliane Lazar-Wesley, PhD, whose telephone number is (703) 305 4059. The

examiner can normally be reached on Monday-Friday from 9:30am to 5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor,

Yvonne Eyler, can be reached on (703) 308-6564.

Official papers filed by fax should be directed to (703) 308 4242. Faxed draft or informal

communications with the examiner should be directed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the Group receptionist whose telephone number is (703) 308-0196.

ELW

March 25, 2002

ty/

WANNE EYLER, PH.D

TECHNOLOGY CENTER 1600